Clinical Trial Update: TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TACTIC using TAA-specific cytotoxic T lymphocytes in breast cancer has completed, with results posted on 2020-04-29.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TACTIC TAA-specific cytotoxic T lymphocytes

Snippet

Sponsor: Baylor College of Medicine | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-04-29